doi: 10.1161/CIRCULATIONAHA.107.741645
(Circulation. 2008;117:3238-3249.)
© 2008 American Heart Association, Inc.
Contemporary Reviews in Cardiovascular Medicine |
Leptin and Cardiovascular Disease
Response to Therapeutic Interventions
From the Division of Cardiology, Gil Heart Center, Gachon University Gil Medical Center, Incheon, Korea (K.K.K., S.M.P.); and Diabetes Unit, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Md (M.J.Q.).
Correspondence to Kwang Kon Koh, MD, PhD, Vascular Medicine and Atherosclerosis Unit, Division of Cardiology, Gachon University Gil Medical Center, 1198 Kuwol-dong, Namdong-gu, Incheon, South Korea 405-760. E-mail kwangk{at}gilhospital.com
Key Words: atherosclerosis • cardiovascular diseases • diabetes mellitus • drugs • hypertension • insulin • obesity
 |
Introduction |
|---|
 Top Introduction Biology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
Leptin, a 16-kDa hormone identified and cloned in 1994, is synthesized and secreted specifically from white adipose cells.1 Leptin has a variety of important central and peripheral actions to regulate energy balance and metabolism, fertility, and bone metabolism that are mediated by specific cell surface leptin receptors.2,3 Importantly, leptin may also exert actions related to cardiovascular homeostasis that are potentially atherogenic, thrombotic, and angiogenic.4–6 Leptin has peripheral actions to stimulate vascular inflammation, oxidative stress, and vascular smooth muscle hypertrophy that may contribute to pathogenesis of type 2 diabetes mellitus, hypertension, atherosclerosis, and coronary heart disease.3,4,7
Insulin resistance,8 systemic hypertension, and hypercholesterolemia9 all contribute independently to vascular endothelial dysfunction that promotes atherosclerosis and coronary heart disease. Reciprocal relationships between endothelial dysfunction and insulin resistance are characterized by impaired insulin-stimulated nitric oxide (NO) production from endothelium that decreases blood flow to insulin target tissues.10,11 Relationships among obesity, metabolic syndrome, diabetes mellitus, and their cardiovascular complications are well established. However, the mechanisms by which excess adiposity causes both insulin resistance and vascular dysfunction are not well understood. Direct vascular effects of adipokines such as leptin are attractive candidates that may help to explain underlying pathophysiological mechanisms.
Several clinical studies demonstrate that hyperleptinemia predicts acute cardiovascular events, restenosis after coronary injury such as angioplasty, and cerebral stroke independent of traditional risk factors.12–14 Leptin-deficient hyperlipidemic mice (ob/ob; apolipoprotein E [apoE]–/– mice) develop significantly less atherosclerosis than apoE–/– mice on an atherogenic diet. Exogenous leptin significantly increases atherosclerotic areas in apoE–/– mice. Taken together, these findings support the notion that leptin accelerates atherosclerosis.15
By contrast, some data indicate that leptin may protect against atherosclerosis in specific animal models. For example, low-density lipoprotein–receptor knockout mice lacking leptin (LDLR–/– ob/ob) develop more atherosclerotic lesions than LDLR–/– control mice.16 Moreover, in 207 women with normal glucose tolerance, impaired glucose tolerance, or type 2 diabetes mellitus, low plasma leptin predicted cardiovascular mortality during a 7-year follow-up period.17 Thus, the net effects of leptin on cardiovascular pathophysiology are complex and not completely understood.
In this review, we discuss cardiovascular actions of leptin related to atherosclerosis, insulin resistance, and hypertension. Particular emphasis is given to insights derived from therapeutic interventions with lifestyle modification, cardiovascular drugs, antidiabetic drugs, and other related treatments.
|
Biology and Metabolism of Leptin |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
The adipocyte is an active endocrine secretory cell releasing free fatty acids and several cytokines and hormones including leptin, adiponectin, tumor necrosis factor-
, and angiotensin II (Ang II).18 Leptin is primarily involved in central regulation of food intake and energy expenditure. Leptin was identified by positional cloning of the ob gene, which determines obesity in ob/ob mice.1 Leptin may participate in several mechanisms of disease associated with obesity. It acts on a specific receptor located in the hypothalamus to decrease appetite and increase energy expenditure. Thus, adipose cell–derived leptin functions as the afferent component of a negative feedback loop that helps to maintain stable adipose tissue mass.2,3 Leptin acts on target cells through plasma membrane receptors (6 isoforms, Ob-Ra through Ob-Rf). Ob-Rb, known as the "long" isoform, is highly expressed in hypothalamus and mediates the anorectic effect of leptin. Other receptor isoforms such as Ob-Ra, Ob-Rc, Ob-Rd and Ob-Rf ("short" isoform) are expressed in peripheral tissues. |
Leptin Resistance |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
In obesity, elevated leptin levels are not sufficient to prevent dysregulation of energy balance, suggesting that obese people are leptin resistant.3 Although most cases of human obesity are associated with hypothalamic leptin resistance, little is known about the peripheral effects of leptin in obese individuals. According to the concept of selective leptin resistance,19 only the anorectic effect of leptin is impaired, whereas its other activities are maintained in obese subjects. Because many potentially proatherogenic effects of leptin have been described, hyperleptinemia may contribute to atherogenesis in obese individuals. The observation that leptin-deficient ob/ob mice are protected from arterial thrombosis or neointimal hyperplasia induced by arterial injury is consistent with this hypothesis.4 An alternative possibility is that hyperleptinemia is not causally linked to atherogenesis but only reflects the state of leptin resistance. Moreover, leptin resistance rather than hyperleptinemia may also contribute to atherosclerosis because of impairment of the beneficial effects of leptin.4
The mechanisms underlying leptin resistance are still being defined. In human blood, several serum leptin–interacting proteins have been isolated, including C-reactive protein (CRP). Human CRP directly inhibits binding of leptin to its receptors and blocks its ability to signal in cultured cells. In vivo, infusion of human CRP into ob/ob mice impairs the ability of leptin to promote satiety and weight reduction. In mice that express a transgene encoding human CRP, the actions of human leptin are blunted.20
In addition to acquired leptin resistance in obesity, leptin resistance may also be determined by genetic factors. For example, db/db mice bear a missense mutation within the leptin receptor gene. Obese Zucker fatty rats and fa/fa mice have an amino acid substitution within the extracellular portion of the leptin receptor, resulting in reduced affinity for leptin. Rare examples exist of human leptin and leptin receptor mutations causing monogenic forms of obesity.21
|
Atherogenic Effects of Leptin |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
Leptin and Endothelial Cells
Functional leptin receptors are present on endothelial cells. However, the actions of leptin to modulate endothelial function remain controversial. In vitro studies demonstrate that leptin at high concentrations elicits endothelium-dependent NO-mediated vasorelaxation in rats.22 In addition, leptin may upregulate inducible NO synthase to generate large amounts of NO that impair endothelial function and promote atherogenesis by inducing oxidative stress.23 When it is exposed to free radicals generated from oxidative stress, NO may undergo conversion to toxic molecules such as peroxynitrite that impair endothelial function.9,23,24 Leptin at pathophysiologically relevant "obese-range" concentrations (but not at low physiological concentrations) impairs NO-dependent vasorelaxation induced by acetylcholine both in vitro and in vivo.25
Several human studies suggest that leptin contributes to endothelial dysfunction or damage in some pathological states.15,26–28 By contrast, no correlation between leptin and endothelial function is observed in healthy adolescents29 and hypertensive patients.30 Thus, the role of leptin in regulating endothelial function in humans remains controversial and may depend on the context of cardiovascular pathophysiology that is present or absent.
Leptin and Lipid Profile
Leptin stimulates lipoprotein lipase secretion in cultured human and murine macrophages.31 Leptin increases accumulation of cholesterol esters in foam cells, especially at high glucose concentrations.32 However, under normoglycemic conditions leptin may protect macrophages from cholesterol overload.33 Several studies demonstrate an inverse relationship between leptin and high-density lipoprotein (HDL) cholesterol and/or apolipoprotein A-I in humans.34 Leptin promotes hepatic HDL clearance by upregulating scavenger receptor type B1 and decreases plasma HDL level in mice.35 Thus, in the context of hyperglycemia, leptin may impair cholesterol removal from peripheral tissues by lowering HDL and unfavorably affect local cholesterol balance in diabetic patients.
Leptin and Inflammatory Markers
Leptin potentiates secretion of tumor necrosis factor and interleukins 2 and 6,36 increases generation and accumulation of reactive oxygen species, and enhances expression of monocyte chemoattractant protein-1.37 Leptin stimulates production of proinflammatory cytokines and enhances production of Th1-type cytokines.38 In endothelial cells, leptin stimulates transforming growth factor-β synthesis.39
Physiological concentrations of leptin stimulate expression of CRP in primary human hepatocytes.20 We observed correlations between plasma leptin and plasma CRP levels.28 However, this was not observed in another study30 in patients with hypertension. Thus, the ability of leptin to promote proinflammatory signaling through cytokines and growth factors may contribute to endothelial dysfunction, atherosclerosis, and insulin resistance in hyperleptinemic states.
Leptin and Smooth Muscle Cells
Leptin stimulates migration and proliferation of vascular smooth muscle cells and expression of matrix metalloproteinase-2 in human aorta in vitro.40 Interestingly, stretching the vascular wall induces expression of both leptin and its receptor in rabbit portal vein.41 Leptin stimulates synthesis and secretion of endothelin-1 in human umbilical vein endothelial cells42 and expression of preproendothelin-1 and endothelin ETA receptor genes, angiotensinogen, and angiotensin type 1 receptor expression in rabbit portal vein smooth muscle cells.41 Finally, leptin stimulates osteoblastic differentiation and hydroxyappatite production by calcifying vascular smooth muscle cells.43
Leptin and Reactive Oxidative Stress
Ob/ob mice are characterized by impaired antioxidant defense, as evidenced by reduced activity of catalase, glutathione peroxidase, and glutathione reductase. Leptin therapy corrects these abnormalities.44 Leptin may increase oxidative stress through multiple mechanisms. In bovine aortic endothelial cells, leptin increases formation of reactive oxygen species in a process coupled with increased fatty acid oxidation and activation of protein kinase A.37 In rats, chronic induction of hyperleptinemia decreases paraoxonase 1 activity. This is followed by increased plasma and urinary concentration of isoprostanes.45 Leptin treatment is also associated with increases in other lipid peroxidation products such as malondialdehyde and 4-hydroxyalkenals in renal tissue.
Leptin increases NADPH oxidase expression and activity in isolated murine cardiomyocytes. This effect is attenuated by endothelin receptor antagonists.46 Paraoxonase 1 activity is decreased in obese women compared with normal-weight controls and inversely correlates with plasma leptin.47 Thus, in hyperleptinemic states such as obesity, leptin may increase oxidative stress through multiple mechanisms.
Leptin and Thrombosis
Leptin increases expression of P-selectin on human platelets in vitro.48 Interestingly, enhancement of the effects of leptin on ADP-induced aggregation is attenuated in platelets obtained from overweight or obese individuals compared with normal-weight subjects.49 However, in other studies, no effect of leptin is observed at concentrations up to 500 ng/mL from normal-weight or obese subjects.50
In 44 obese women, plasma leptin significantly correlates with urinary excretion of 11-dehydrothromboxane B2.51 Caloric restriction reduces leptin levels and is associated with reduced platelet activity. This is reflected by decreased plasma concentration of P-selectin. In men with ischemic heart disease, leptin also positively correlates with the plasma concentration of plasminogen activator inhibitor-1.52 In the Health Professionals Follow-up Study, leptin significantly correlates with fibrinogen and von Willebrand factor.53 In a Swedish population-based study, leptin positively correlates with plasma fibrinogen and inversely correlates with tissue plasminogen activator concentration in plasma.54 An inverse relationship between leptin and 2 inhibitors of coagulation, protein C and tissue factor pathway inhibitor, is also noted in patients with end-stage renal disease.55 Taken together, these data suggest that in some contexts leptin may contribute to platelet hyperactivity and a pathological shift in the coagulation-fibrinolysis balance observed in the metabolic syndrome.
Leptin and Ang II
Ang II increases leptin synthesis in cultured adipose cells56 and in rats in vivo.57 Adipose tissue–derived Ang II and leptin may act synergistically to promote obesity-related hypertension. This hypothesis is supported by epidemiological observations demonstrating that plasma renin activity, serum angiotensinogen, and leptin levels are strongly correlated in lean and obese normotensive and hypertensive subjects.58,59 Ang II also potentiates sympathetic nervous system activity. Given that leptin increases sympathetic activity,60 obese subjects with activation of the renin-angiotensin system may have enhanced sympathetically mediated vasoconstriction in response to leptin. Differential effects of local versus systemic Ang II are observed in the regulation of leptin release from rat adipocytes. Incubation of adipocytes with Ang II results in increased leptin mRNA expression and leptin release. Basal and Ang II–stimulated release of leptin from isolated adipocytes is initially increased; thereafter, leptin release declines to levels less than those of control. Infusion of Ang II increases catecholamine turnover in adipose tissue. Moreover, sympathetic blockade eliminates differences in plasma leptin concentration between saline- and Ang II–infused rats.57 Thus, locally produced Ang II may directly increase leptin secretion from adipocytes. However, with systemic elevations in Ang II, sympathetic activation may counterbalance effects from locally produced Ang II.
|
Leptin and Insulin |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
Insulin potentiates leptin-induced NO release by enhancing leptin-stimulated phosphorylation of Akt and endothelial NO synthase. This raises the possibility of cross talk between insulin and leptin signaling.61 By contrast, leptin does not alter mesenteric blood flow in conscious rats treated with NO synthase inhibitors or
-adrenergic blockers, despite increased sympathetic activity.62 These results suggest that leptin alters the NO-dependent vascular reactivity of resistance vessels. Intriguingly, systemic leptin administration does not attenuate vasoconstriction caused by sympathetic nerve stimulation, suggesting that direct vasodilator actions of leptin may be insufficient to oppose sympathetically mediated vasoconstriction.63 Thus, although leptin may possess beneficial NO-dependent vasodilator actions, the net effects of leptin on vascular function in vivo are still unclear and may depend on the presence or absence of other metabolic and cardiovascular pathophysiology.5 Leptin increases insulin sensitivity in rats and may improve vascular responses to insulin in states of insulin resistance.64 Leptin secretion by adipocytes is stimulated by insulin, and plasma leptin significantly correlates with plasma insulin.65 By contrast, under some conditions, leptin negatively regulates insulin signaling66 and glucose uptake.67
Leptin increases free fatty acid oxidation in isolated mouse soleus muscle by 42%, whereas insulin decreases this by 40%. When both hormones are administered, leptin attenuates both the antioxidative and lipogenic effects of insulin by 50%.68 Leptin attenuates the antioxidative, lipogenic actions of insulin on muscle free fatty acid metabolism via a peripheral mechanism, whereas the effects of leptin in modulating insulin-stimulated glucose disposal appear to occur via a central mechanism.2 Recombinant mouse leptin inhibits glycogen synthesis in soleus muscle of ob/ob mice in the presence of insulin.69 By contrast, leptin increases glycogen synthesis in cultured C2C12 muscle cells.70
Important peripheral actions of leptin include inhibition of insulin biosynthesis and secretion in pancreatic β-cells. In turn, insulin stimulates leptin secretion from adipose tissue, establishing a hormonal regulatory feedback loop, the so-called adipoinsular axis. Multiple signal transduction pathways are involved in leptin signaling in pancreatic β-cells. In most overweight individuals, physiological regulation of body weight by leptin seems to be disturbed, representing "leptin resistance." This leptin resistance at the level of the pancreatic β-cell may contribute to dysregulation of the adipoinsular axis and contribute to development of hyperinsulinemia and manifest type 2 diabetes mellitus in overweight patients.3
Leptin may potentiate pressor effects of hyperinsulinemia in insulin-resistant states. Therefore, interactions between Ang II and insulin with leptin may have deleterious cardiovascular effects in the setting of obesity.
|
Leptin and Hypertension |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
Leptin administered short term has no net effect on blood pressure under healthy conditions. In lean animals, leptin activates the sympathetic nervous system. However, this is balanced by NO-dependent vasorelaxation and natriuresis so that blood pressure does not change. By contrast, chronic hyperleptinemia increases blood pressure because acute depressor effects are impaired and/or additional sympathetic nervous system–independent pressor effects appear, such as oxidative stress, NO deficiency, enhanced renal Na+,K+-ATPase activity, and Na+ reabsorption and overproduction of endothelin.7,60,71 Indeed, in obese animals, the effects of leptin on NO and natriuresis are impaired.7 Chronic leptin-dependent increases in sympathetic nervous activity and arterial pressure are mediated through increases in central nervous system corticotrophin-releasing factor activity.72
Although a cause-and-effect relationship between leptin and high blood pressure in humans has not been demonstrated directly, many clinical studies have shown elevated plasma leptin in patients with essential hypertension. In addition, a significant positive correlation exists between leptin and blood pressure independent of body adiposity in both normotensive and hypertensive individuals.73 Correlations between leptin and blood pressure are influenced by gender. Despite higher serum leptin levels in women, leptin and blood pressure associations have been reported more frequently in men than in women, regardless of hypertension and adiposity.74 Ethnic and racial background may also influence the relationship between leptin and blood pressure. We did not observe significant correlations between plasma leptin levels and blood pressure before efonidipine therapy.29
|
Results From Clinical Surveys |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
Plasma leptin is higher in male patients who subsequently develop first-ever myocardial infarction than in control subjects.75 Leptin is also an independent predictor of myocardial infarction in men and especially women with arterial hypertension.76 Plasma leptin is higher in offspring with paternal history of premature myocardial infarction than in those without family history of cardiovascular events.77 Elevated plasma leptin predicts coronary events in men during a 5-year follow-up period.12 Plasma leptin is higher in patients who subsequently develop restenosis after coronary angioplasty than in those who do not.13 Leptin is an independent predictor of hemorhagic stroke in men and women14 and of stroke (ischemic and hemorrhagic stroke) in men but not in women.78 Furthermore, leptin is a predictor of myocardial infarction, coronary events, and stroke independent of body mass index (BMI).12,14,75,76,78 Significant correlations between leptin and intima-media thickness of the common carotid artery are present in obese individuals without diabetes mellitus.79 Brachial artery distention during systolic pulse wave inversely correlates with plasma leptin in healthy adolescents.80
By contrast, no correlation between leptin and intima-media thickness is noted in 403 elderly men without ischemic heart disease81 or in children with obesity or type 1 diabetes mellitus.82 Furthermore, leptin does not predict ischemic heart disease in men.83 It is not clear why leptin levels are correlated with preclinical atherosclerosis in some studies but not others. This may depend on the pathophysiological context of the patients studied, medications taken, or other factors.
Leptin is an independent predictor of diabetes mellitus in some studies. In Japanese Americans followed for 5 to 6 years, increased baseline leptin levels are associated with increased risk of developing diabetes mellitus in men but not in women.84 Leptin predicts development of diabetes mellitus in Mauritian men but not women in a population-based study.85 In a prospective study of nondiabetic white men with 5 years of follow-up, higher leptin levels are associated with increased risk of type 2 diabetes mellitus.86 In a population-based study of white subjects, leptin concentrations are 4 times higher in women than in men. BMI, waist circumference, insulin, and triglyceride concentrations are independently and significantly associated with leptin.87 Interestingly, low plasma leptin levels predict cardiovascular mortality.17 This may reflect the fact that both very high and very low BMI values predict increased mortality.
Leptin levels in healthy women are substantially higher than in healthy men. The mechanisms underlying these differences are unknown. Leptin signaling may differ between genders. Women have significantly higher fasting leptin, heart rate, and cardiac sympathetic activity and lower insulin sensitivity. Men show inverse correlations between insulin resistance and heart rate and between insulin resistance and cardiac sympathovagal ratio. Women, by contrast, show no sympathetic activity relationship with insulin resistance but rather an inverse correlation between leptin and the sympathovagal ratio. This suggests that leptin in women is associated with sympathetic activity.88 Spontaneous leptin secretion over 24-hour and 48-hour periods shows a gender-based difference that is significantly higher in women than in men.89 These observations may help to explain the differences in leptin concentrations between men and women.
|
Therapeutic Interventions |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
Therapeutic interventions targeting the "leptin system" may potentially prevent or reduce cardiovascular complications. Clinical studies, including some prospective trials, suggest that high plasma leptin levels are associated with development of atherosclerosis and its complications. However, the question of whether hyperleptinemia directly promotes atherosclerosis in obese subjects is still unresolved. Indeed, all evidence currently available is circumstantial, associative, and sometimes contradictory. It seems that the most convincing evidence of the proatherogenic effects of leptin is obtained by examining manipulations that reduce leptin signaling in hyperleptinemic obese animals.
Lifestyle Modifications
Leptin levels decrease after initiation of a diet to induce weight loss90 or weight loss programs.27,91 One major reason for the long-term failure of these therapies is the fact that weight-reduced obese and overweight individuals develop inappropriate hunger and are leptin resistant. The relationship between a fish diet or a vegetarian diet and leptin in Africans was examined. In both men and women, fish consumption is associated with lower plasma leptin levels than are vegetable diets.92
Recombinant Human Leptin
Patients with lipodystrophies develop severe insulin resistance, fatty liver, and hypertriglyceridemia as a result of excess fat being deposited in liver and muscle tissue. Because of reduced fat tissue, leptin levels are low. Leptin treatment is beneficial in these cases.93 Leptin therapy is also beneficial in rare cases of monogenic forms of human obesity caused by leptin mutations.21
Drugs
Renin-Angiotensin System Blocking Agents
Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension.94 Ang II type 1 receptor blocker treatment significantly decreases mass of both subcutaneous and mesenteric adipose tissue, improves insulin resistance, and reduces plasma leptin and leptin mRNA in adipose tissue.95 Improvement of insulin resistance by Ang II type 1 receptor blockers may be attributed, in part, to reduction of adipose tissue. Losartan treatment has no significant effect on leptin concentrations in patients with hypertension.96 In patients with mild or moderate hypertension, perindopril or felodipine does not decrease leptin and insulin levels. However, pindolol markedly suppresses leptin levels without influencing insulin levels.97 In obese patients with mild to moderate essential hypertension, felodipine has no effect on plasma leptin and insulin sensitivity. However, valsartan significantly reduces plasma leptin, insulin resistance, and BMI.98 We compared the effects of ramipril, candesartan, and ramipril combined with candesartan in 34 patients with hypertension.30 Ramipril and candesartan therapies decrease plasma leptin levels relative to respective baseline measurements by 11% and 5%, respectively. Combination therapy decreases plasma leptin levels relative to respective baseline measurements by 21%, and the magnitude of reduction with combination therapy is greater than either ramipril or candesartan monotherapy (Figure 1) despite no change in BMI after therapies. In another study, we compared effects of placebo, atenolol 100 mg, amlodipine 10 mg, hydrochlorothiazide 50 mg, ramipril 10 mg, or candesartan 16 mg in 31 patients with hypertension.99 Ramipril, candesartan, and amlodipine therapies significantly decrease plasma leptin levels relative to respective baseline measurements by 16%, 12%, and 12%, respectively. Atenolol therapy increases plasma leptin levels relative to respective baseline measurements by 15%. Thiazide therapy does not change leptin levels. Ramipril, candesartan, and amlodipine therapies significantly decrease leptin levels more than atenolol or thiazide therapies (Figure 2) despite no change in BMI after therapies.
|
|
Calcium Channel Blockers
We observe significant correlations between baseline BMI and baseline leptin levels in patients with hypertension.28 In this study, efonidipine treatment also significantly decreases plasma leptin by 12%. Correlations are noted between percent changes in flow-mediated dilation and leptin levels (r=–0.467, P=0.003) and between percent changes in plasma levels of malondialdehyde and percent changes in plasma levels of leptin (r=0.364, P=0.025) after efonidipine therapy. Significant correlations exist between pretreatment insulin levels and pretreatment leptin levels (r=0.514, P<0.001) and between percentage changes in insulin levels and percentage changes in leptin levels (r=0.409, P=0.011) after efonidipine therapy. Significant inverse correlations exist between pretreatment plasma leptin levels and pretreatment insulin sensitivity index (Quantitative Insulin-Sensitivity Check Index [QUICKI]) (r=–0.431, P=0.007) and between percent changes in plasma leptin levels and percent changes in QUICKI (r=–0.400, P=0.013; Figure 3) after efonidipine therapy.
|
β-Blockers
Atenolol therapy increases plasma leptin levels.99 Pindolol has a marked suppressive effect on leptin levels.97 The effects of other drugs in this class on leptin have not yet been investigated.
Thiazides
Thiazide therapy does not significantly change plasma leptin levels.99
Statins
Atorvastatin dose-dependently inhibits leptin secretion and mRNA expression in cultured adipocytes.100 However, pravastatin in healthy human volunteers does not change leptin levels.101 In nondiabetic patients, lovastatin and gemfibrozil do not affect serum leptin concentration, whereas lovastatin adversely affects insulin sensitivity.102
Peroxisome Proliferator-Activated Receptor Agonists
Treatment of rats with the peroxisome proliferator-activated receptor- activator fenofibrate does not change adipose tissue and body weight and has no significant effect on leptin mRNA levels. Thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.103 Rosiglitazone and gemfibrozil decrease serum glucose, insulin, and leptin levels in diet-induced obese rats.104 Peroxisome proliferator-activated receptor- activation significantly decreases serum leptin levels in obese diabetic mice, whereas rosiglitazone does not.105
1-Receptor Blockers
Bunazosin hydrochloride reduces plasma leptin levels and improves insulin resistance in hypertensive patients with obesity and hyperleptinemia.106
Metformin
Metformin effectively reduces fasting insulin and leptin in 31 morbidly obese, nondiabetic subjects with BMI >30.107
Dopamine D2 Receptor Agonist
Activation of dopamine D2 receptors by bromocriptine lowers circulating leptin levels in obese women.108
Glucocorticoid
Adipocyte leptin mRNA increases after hydrocortisone infusion.109 In obese women and in normal-weight subjects, dexamethasone induces plasma leptin elevations that are unrelated to body fat distribution and insulin sensitivity.110 Indeed, metyrapone-induced inhibition of cortisol biosynthesis results in hypoleptinemia in obese subjects.111
Smoking
Nicotine increases plasma adrenaline levels. Plasma leptin levels in smoking men are lower than in nonsmokers. Nicotine may indirectly reduce leptin secretion via enhanced plasma catecholamine concentration.112 Murine recombinant leptin induces release of both epinephrine and norepinephrine from chromaffin cells. Moreover, leptin enhances nicotine-induced increases in catecholamines.113 Nicotine downregulates plasma leptin concentration and leptin mRNA. On the other hand, long-term nicotine administration increases expression of OB-Rb mRNA and OB-R mRNA in the medial basal hypothalamus compared with control rats.114 Indeed, leptin levels are higher in nicotine gum chewers and smokers than in the nonsmoking matched middle-aged men.115
Miscellaneous
All-trans retinoic acid reduces both expression and secretion of leptin in human and rodent adipose tissue.116 After 12 weeks of a high–glycemic index starch diet, both plasma leptin and ob mRNA are decreased compared with a low–glycemic index diet in rats.117 N-3 polyunsaturated fatty acids decrease leptin gene expression in human trophoblast cell lines.118 However, this treatment upregulates plasma leptin in insulin-sensitive rats.119 On a rapeseed oil diet, serum leptin concentrations increase slightly in men but decrease distinctly in women. Serum leptin levels may be affected by the large amount of -linolenic acid in rapeseed oil. However, questions remain about why this diet differentially affects serum leptin in men and women.120
|
Future Prospects |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
In some contexts, leptin seems to promote both atherogenesis and and insulin resistance. By contrast, in other contexts, leptin may have antiatherogenic and insulin-sensitizing effects. These opposing actions of leptin are maintained in balance under healthy conditions. In pathological conditions such as obesity, the balance of leptin actions may shift to stimulate vascular inflammation, oxidative stress, and vascular smooth muscle hypertrophy. These actions may contribute to the pathogenesis of hypertension, atherosclerosis, left ventricular hypertrophy, and type 2 diabetes mellitus. Several clinical studies demonstrate that hyperleptinemia predicts acute cardiovascular events, restenosis after coronary injury, and cerebral stroke independent of traditional risk factors.12–14 By contrast, some data indicate that leptin may protect against atherosclerosis in specific animal models.15 Indeed, low plasma leptin predicts cardiovascular mortality.17
Leptin may potentiate the pressor effects of hyperinsulinemia in insulin-resistant states. Therefore, interactions between Ang II and insulin with leptin under insulin-resistant conditions may have deleterious cardiovascular effects in obesity. Positive and independent associations between leptin and insulin resistance suggest a role for leptin in the metabolic syndrome.87 However, human studies specifically examining the interactions between cardiovascular actions of insulin and leptin in normal and pathological states are lacking.
The antiatherogenic and insulin-sensitizing effects of leptin are summarized in Table 1. Therapeutic interventions with lifestyle modification, cardiovascular drugs, antidiabetic drugs, and miscellaneous therapies may be promising but still controversial (Table 2). Prospective studies are needed to examine the ability of decreases in leptin levels and increases in insulin sensitivity to improve primary end points including incidence of diabetes mellitus and outcomes of cardiovascular events. We summarize the stimulators and inhibitors of leptin expression in Table 3. It is possible that recombinant leptin may have a beneficial therapeutic role in the treatment and prevention of cardiovascular diseases in the future.
|
|
|
|
Acknowledgments |
|---|
Sources of Funding
This study was supported in part by grants from Established Investigator Award (2007-1), Gil Medical Center, Gachon University (Dr Koh), and by the Intramural Research Program, National Center for Complementary and Alternative Medicine, National Institutes of Health (Dr Quon).
Disclosures
None.
|
References |
|---|
|
TopIntroductionBiology and Metabolism of...Leptin ResistanceAtherogenic Effects of LeptinLeptin and InsulinLeptin and HypertensionResults From Clinical SurveysTherapeutic InterventionsFuture ProspectsReferences |
|---|
1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372: 425–432.[CrossRef][Medline] [Order article via Infotrieve]
2. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002; 26: 1407–1433.[CrossRef][Medline] [Order article via Infotrieve]
3. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes. 2004; 53 (suppl 1): S152–S158.
4. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006; 189: 47–60.[CrossRef][Medline] [Order article via Infotrieve]
5. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2004; 13: 215–223.[Medline] [Order article via Infotrieve]
6. Werner N, Nickenig G. From fat fighter to risk factor: the zigzag trek of leptin. Arterioscler Thromb Vasc Biol. 2004; 24: 7–9.
7. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens. 2006; 24: 789–801.[Medline] [Order article via Infotrieve]
8. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007; 28: 463–491.
9. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000; 47: 648–657.
10. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113: 1888–1904.
11. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Op Lipidol. 2007; 18: 58–65.[Medline] [Order article via Infotrieve]
12. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001; 104: 3052–3056.
13. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003; 108: 2074–2081.
14. Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L, Hallmans G, Olsson T. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 1999; 30: 328–337.
15. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, Kitagawa M, Kondo K, Chait A, Shimokado K. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis. 2008; 196: 68–75.[CrossRef][Medline] [Order article via Infotrieve]
16. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001; 276: 37402–37408.
17. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care. 2003; 26: 2883–2889.
18. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007; 49: 531–538.
19. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002; 20: 1245–1250.[CrossRef][Medline] [Order article via Infotrieve]
20. Ke Chen, Fanghong Li, Ji Li, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006; 12: 425–432.[CrossRef][Medline] [Order article via Infotrieve]
21. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006; 27: 710–718.
22. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, Trimarco B. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000; 49: 293–297.[Abstract]
23. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005; 26: 33–65.[CrossRef][Medline] [Order article via Infotrieve]
24. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998; 44 (pt 2): 1809–1819.
25. Knudson JD, Dincer UD, Zhang C, Swafford AN Jr, Koshida R, Picchi A, Focardi M, Dick GM, Tune JD. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol. 2005; 289: H48–H56.
26. Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J. High serum leptin is associated with attenuated coronary vasoreactivity. Obes Res. 2003; 11: 776–782.[Medline] [Order article via Infotrieve]
27. Porreca E, Di Febbo C, Fusco L, Moretta V, Di Nisio M, Cuccurullo F. Soluble thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women. Atherosclerosis. 2004; 172: 175–180.[CrossRef][Medline] [Order article via Infotrieve]
28. Koh KK, Quon MJ, Lee SJ, Han SH, Ahn JY, Kim JA, Chung WJ, Lee Y, Shin EK. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in non-diabetic patients with hypertension. Diabetes Care. 2007; 30: 1605–1607.
29. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002; 106: 1919–1924.
30. Koh KK, Quon MJ, Han SH, Han SH, Ahn JY, Chung WJ, Kim JA, Shin EK. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007; 28: 1440–1447.
31. Maingrette F, Renier G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes. 2003; 52: 2121–2128.
32. O'Rourke L, Yeaman SJ, Shepherd PR. Insulin and leptin acutely regulate cholesterol ester metabolism in macrophages by novel signaling pathways. Diabetes. 2001; 50: 955–961.
33. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem. 2002; 277: 42557–42562.
34. Rainwater DL, Comuzzie AG, VandeBerg JL, Mahaney MC, Blangero J. Serum leptin levels are independently correlated with two measures of HDL. Atherosclerosis. 1997; 132: 237–243.[CrossRef][Medline] [Order article via Infotrieve]
35. Lundasen T, Liao W, Angelin B, Rudling M. Leptin induces the hepatic high density lipoprotein receptor scavenger receptor B type I (SR-BI) but not cholesterol 7_-hydroxylase (Cyp7a1) in leptin deficient (ob/ob) mice. J Biol Chem. 2003; 278: 43224–43228.
36. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J. 1998; 12: 57–65.
37. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276: 25096–25100.
38. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol. 2003; 133: 11–19.[CrossRef][Medline] [Order article via Infotrieve]
39. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999; 56: 860–872.[CrossRef][Medline] [Order article via Infotrieve]
40. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes. 2005; 54: 2227–2234.
41. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1 dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther. 2005; 315: 1075–1084.
42. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002; 90: 711–718.
43. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001; 88: 954–960.
44. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos. 1999; 27: 695–700.
45. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis. 2003; 170: 21–29.[CrossRef][Medline] [Order article via Infotrieve]
46. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension. 2006; 47: 222–229.
47. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005; 90: 1728–1733.
48. Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R, Eigenthaler M, Lohmann T. Differences in platelet activation by prolactin and leptin. Horm Metab Res. 2004; 36: 453–457.[CrossRef][Medline] [Order article via Infotrieve]
49. Corsonello A, Perticone F, Malara A, De Domenico D, Loddo S, Buemi M, Ientile R, Corica F. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord. 2003; 27: 566–573.[CrossRef][Medline] [Order article via Infotrieve]
50. Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir IC, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res. 2001; 9: 627–630.[Medline] [Order article via Infotrieve]
51. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002; 288: 2008–2014.
52. Thogersen AM, Soderberg S, Jansson JH, Dahlén G, Boman K, Nilsson TK, Lindahl B, Weinehall L, Stenlund H, Lundberg V, Johnson O, Ahrén B, Hallmans G. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2004; 11: 33–40.[CrossRef][Medline] [Order article via Infotrieve]
53. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis. 2001; 157: 495–503.[CrossRef][Medline] [Order article via Infotrieve]
54. Soderberg S, Olsson T, Eliasson M, Johnson O, Ahrén B. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med. 1999; 245: 533–543.[CrossRef][Medline] [Order article via Infotrieve]
55. Ma
yszko J, Woczy
ski S, Mayszko J, My
liwiec M. Leptin correlates with some hemostatic parameters in CAPD patients. Nephron. 2002; 92: 721–724.[CrossRef][Medline]
[Order article via Infotrieve]
56. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res. 2005; 13: 969–973.[Medline] [Order article via Infotrieve]
57. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology. 2004; 145: 169–174.
58. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens. 1998; 16: 1475–1480.[CrossRef][Medline] [Order article via Infotrieve]
59. Adamczak M, Kokot F, Wiecek AW. Relationship between plasma rennin profile and leptinaemia in patients with essential hypertension. J Hum Hypertens. 2000; 14: 503–509.[CrossRef][Medline] [Order article via Infotrieve]
60. Correia ML, Morgan DA, Sivitz WI, Mark AL, Haynes WG. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 2001; 37: 936–942.
61. Vecchione C, Aretini A, Maffei A, Marino G, Selvetella G, Poulet R, Trimarco V, Frati G, Lembo G. Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension. 2003; 42: 166–170.
62. Mitchell JL, Morgan DA, Correia ML, Mark AL, Sivitz WI, Haynes WG. Does leptin stimulate nitric oxide to oppose the effects of sympathetic activation? Hypertension. 2001; 38: 1081–1086.
63. Jalali A, Morgan DA, Sivitz WI, Correia ML, Mark AL, Haynes WG. Does leptin cause functional peripheral sympatholysis? Am J Hypertens. 2001; 14: 615–618.[CrossRef][Medline] [Order article via Infotrieve]
64. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology. 1997; 138: 3395–3401.
65. de Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, Dowse G, Alberti KG. Hyperleptinaemia: the missing link in the metabolic syndrome? Diabet Med. 1997; 14: 200–208.[CrossRef][Medline] [Order article via Infotrieve]
66. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996; 274: 1185–1188.
67. Hennige AM, Stefan N, Kapp K, Lehmann R, Weigert C, Beck A, Moeschel K, Mushack J, Schleicher E, Häring HU. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J. 2006; 20: 1206–1208.
68. Muoio DM, Dohm GL, Fiedorek FT, Tapscott EB, Coleman RA. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes. 1997; 46: 1360–1363.[Abstract]
69. Liu Y-L, Emilsson V, Cawthorne MA. Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob=ob) mice. FEBS Lett. 1997; 411: 351–355.[CrossRef][Medline] [Order article via Infotrieve]
70. Berti L, Kellerer M, Capp E, Haring HU. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes; evidence for a PI3-kinase mediated effect. Diabetologia. 1997; 40: 606–609.[CrossRef][Medline] [Order article via Infotrieve]
71. Beltowski J, Wojcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci. 2004; 74: 2987–3000.[CrossRef][Medline] [Order article via Infotrieve]
72. Correia ML, Morgan DA, Mitchell JL, Sivitz WI, Mark AL, Haynes WG. Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure. Hypertension. 2001; 38: 384–388.
73. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997; 10: 1171–1174.[CrossRef][Medline] [Order article via Infotrieve]
74. Mallamaci F, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tripepi R, Zoccali C. Gender-dependent differences in plasma leptin in essential hypertension. Am J Hypertens. 2000; 13: 914–920.[CrossRef][Medline] [Order article via Infotrieve]
75. Soderberg S, Ahren B, Jansson JH, Sjöström LG, Agren A, Johansson L, Weinehall L, Olsson T. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999; 246: 409–418.[CrossRef][Medline] [Order article via Infotrieve]
76. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Press. 2004; 13: 243–246.[CrossRef][Medline] [Order article via Infotrieve]
77. Makris TK, Hatzizacharias AN, Krespi PG, Chronakis EV, Vythoulkas JS, Maria K, Tsoukala CG, Votteas VV. Markers of risk in young offspring with paternal history of myocardial infarction. Int J Cardiol. 2003; 89: 287–293.[CrossRef][Medline] [Order article via Infotrieve]
78. Soderberg S, Stegmayr B, Stenlund H, Sjöström LG, Agren A, Johansson L, Weinehall L, Olsson T. Leptin, but not adiponectin, predicts stroke in males. J Intern Med. 2004; 256: 128–136.[CrossRef][Medline] [Order article via Infotrieve]
79. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, Giorgino R, De Pergola G. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001; 25: 805–810.[Medline] [Order article via Infotrieve]
80. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002; 106: 1919–1924.
81. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003; 157: 25–31.
82. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes. 2004; 112: 378–382.[CrossRef][Medline] [Order article via Infotrieve]
83. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ, Després JP. Leptinemia is not a risk factor for ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Diabetes Care. 1998; 21: 782–786.[Abstract]
84. McNeely MJ, Boyko EJ, Weigle DS, Shofer JB, Chessler SD, Leonnetti DL, Fujimoto WY. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care. 1999; 22: 65–70.
85. Söderberg S, Zimmet P, Tuomilehto J, Chitson P, Gareeboo H, Alberti KG, Shaw JE. Leptin predicts the development of diabetes in Mauritian men, but not women: a population-based study. Int J Obes (Lond). 2007; 31: 1126–1133.[CrossRef][Medline] [Order article via Infotrieve]
86. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007; 30: 1200–1205.
87. Ruige JB, Dekker JM, Blum WF, Stehouwer CD, Nijpels G, Mooy J, Kostense PJ, Bouter LM, Heine RJ. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study: the Hoorn Study. Diabetes Care. 1999; 22: 1097–1104.
88. Flanagan DE, Vaile JC, Petley GW, Phillips DI, Godsland IF, Owens P, Moore VM, Cockington RA, Robinson JS. Gender differences in the relationship between leptin, insulin resistance and the autonomic nervous system. Regul Pept. 2007; 140: 37–42.[CrossRef][Medline] [Order article via Infotrieve]
89. Menendez C, Baldelli R, Lage M, Casabiell X, Piñero V, Solar J, Dieguez C, Casanueva FF. The in vitro secretion of human leptin is gender-dependent but independent of the body mass index of the donors. Eur J Endocrinol. 2000; 143: 711–714.[Abstract]
90. Torgerson JS, Carlsson B, Stenlof K Carlsson LM, Bringman E, Sjöström L. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab. 1999; 84: 4197–4203.
91. Geldszus R, Mayr B, Horn R Geisthövel F, von zur Mühlen A, Brabant G. Serum leptin and weight reduction in female obesity. Eur J Endocrinol. 1996; 135: 659–662.
92. Winnicki M, Somers VK, Accurso V, Phillips BG, Puato M, Palatini P, Pauletto P. Fish-rich diet, leptin, and body mass. Circulation. 2002; 106: 289–291.
93. Oral EA, Simha V, Ruiz E Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346: 570–578.
94. Uckaya G, Ozata M, Sonmez A, Kinalp C, Eyileten T, Bingol N, Koc B, Kocabalkan F, Ozdemir IC. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res. 1999; 31: 435–438.[Medline] [Order article via Infotrieve]
95. Umeda M, Kanda T, Murakami M. Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res. 2003; 26: 485–492.[CrossRef][Medline] [Order article via Infotrieve]
96. Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F, Ozata M. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J Renin Angiotensin Aldosterone Syst. 2001; 2: 112–116.
97. Ficek J, Kokot F, Chudek J, Adamczak M, Ficek R, Wieçek A. Influence of antihypertensive treatment with perindopril, pindolol or felodipin on plasma leptin concentration in patients with essential hypertension. Horm Metab Res. 2002; 34: 703–708.[CrossRef][Medline] [Order article via Infotrieve]
98. Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005; 28: 209–214.[CrossRef][Medline] [Order article via Infotrieve]
99. Koh KK, Quon MJ, Han SH. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Circulation. 2006; 114: II-677. Abstract.
100. Zhao SP, Wu ZH. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta. 2005; 360: 133–140.[CrossRef][Medline] [Order article via Infotrieve]
101. Gannagé-Yared MH, Azar RR, Amm-Azar M, Khalifé S, Germanos-Haddad M, Neemtallah R, Halaby G. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism. 2005; 54: 947–951.[CrossRef][Medline] [Order article via Infotrieve]
102. Hung YJ, Pei D, Wu DA, Kuo SW, Fuh MM, Jeng C. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol. J Formos Med Assoc. 1999; 98: 104–110.[Medline] [Order article via Infotrieve]
103. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 1996; 93: 5793–5796.
104. Toruner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Aktürk M, Karakoç A, Ayvaz G, Arslan M. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Horm Metab Res. 2004; 36: 226–230.[CrossRef][Medline] [Order article via Infotrieve]
105. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005; 54: 3358–3370.
106. Ihara S, Shimamoto K, Watanabe H, Sakai R, Kawana M. An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. Hypertens Res. 2006; 29: 805–811.[CrossRef][Medline] [Order article via Infotrieve]
107. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001; 50: 856–861.[CrossRef][Medline] [Order article via Infotrieve]
108. Kok P, Roelfsema F, Frölich M, van Pelt J, Meinders AE, Pijl H. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women. J Clin Endocrinol Metab. 2006; 91: 3236–3240.
109. Askari H, Liu J, Dagogo-Jack S. Hormonal regulation of human leptin in vivo: effects of hydrocortisone and insulin. Int J Obes Relat Metab Disord. 2000; 24: 1254–1259.[CrossRef][Medline] [Order article via Infotrieve]
110. Putignano P, Brunani A, Dubini A, Bertolini M, Pasquali R, Cavagnini F; "Study Group on Obesity" of the Italian Society of Endocrinology. Effect of small doses of dexamethasone on plasma leptin levels in normal and obese subjects: a dose-response study. J Endocrinol Invest. 2003; 26: 111–116.[Medline] [Order article via Infotrieve]
111. Dagogo-Jack S, Tykodi G, Umamaheswaran I. Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans. J Clin Endocrinol Metab. 2005; 90: 5333–5335.
112. Reseland JE, Mundal HH, Hollung K, Haugen F, Zahid N, Anderssen SA, Drevon CA. Cigarette smoking may reduce plasma leptin concentration via catecholamines. Prostaglandins Leukot Essent Fatty Acids. 2005; 73: 43–49.[CrossRef][Medline] [Order article via Infotrieve]
113. Takekoshi K, Motooka M, Isobe K, Nomura F, Manmoku T, Ishii K, Nakai T. Leptin directly stimulates catecholamine secretion and synthesis in cultured porcine adrenal medullary chromaffin cells. Biochem Biophys Res Commun. 1999; 261: 426–431.[CrossRef][Medline] [Order article via Infotrieve]
114. Li MD, Kane JK. Effect of nicotine on the expression of leptin and forebrain leptin receptors in the rat. Brain Res. 2003; 991: 222–231.[CrossRef][Medline] [Order article via Infotrieve]
115. Eliasson B, Smith U. Leptin levels in smokers and long-term users of nicotine gum. Eur J Clin Invest. 1999; 29: 145–152.[CrossRef][Medline] [Order article via Infotrieve]
116. Hollung K, Rise CP, Drevon CA, Reseland JE. Tissue-specific regulation of leptin expression and secretion by all-trans retinoic acid. J Cell Biochem. 2004; 92: 307–315.[CrossRef][Medline] [Order article via Infotrieve]
117. Kabir M, Guerre-Millo M, Laromiguiere M, Slama G, Rizkalla SW. Negative regulation of leptin by chronic high-glycemic index starch diet. Metabolism. 2000; 49: 764–769.[CrossRef][Medline] [Order article via Infotrieve]
118. Reseland JE, Haugen F, Hollung K, Solvoll K, Halvorsen B, Brude IR, Nenseter MS, Christiansen EN, Drevon CA. Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res. 2001; 42: 743–750.
119. Peyron-Caso E, Taverna M, Guerre-Millo M, Véronèse A, Pacher N, Slama G, Rizkalla SW. Dietary (n-3) polyunsaturated fatty acids up-regulate plasma leptin in insulin-resistant rats. J Nutr. 2002; 132: 2235–2240.
120. Kratz M, von Eckardstein A, Fobker M, Buyken A, Posny N, Schulte H, Assmann G, Wahrburg U. The impact of dietary fat composition on serum leptin concentrations in healthy nonobese men and women. J Clin Endocrinol Metab. 2002; 87: 5008–5014.
This article has been cited by other articles:
 |
|
 |
|
  K. K. Koh Distinct Metabolic Effects of Different Classes of Antihypertensive Drugs Hypertension, April 1, 2009; 53(4): e26 - e26. [Full Text] [PDF]
|
|
|
|
|
|
A. Silvani, S. Bastianini, C. Berteotti, C. Franzini, P. Lenzi, V. Lo Martire, and G. Zoccoli Sleep Modulates Hypertension in Leptin-Deficient Obese Mice Hypertension, February 1, 2009; 53(2): 251 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rasouli and P. A. Kern Adipocytokines and the Metabolic Complications of Obesity J. Clin. Endocrinol. Metab., November 1, 2008; 93(11_Supplement_1): s64 - s73. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||